# Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

> **NCT02077166** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 138 (actual)

## Conditions studied

- Relapsed Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Lenalidomide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02077166
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-13
- **Primary completion:** 2020-12-17
- **Final completion:** 2020-12-17
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2022-02-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02077166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02077166, "Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02077166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*